605 related articles for article (PubMed ID: 28754671)
1. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
2. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
[TBL] [Abstract][Full Text] [Related]
5. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
6. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
7. Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.
Sharif GM; Schmidt MO; Yi C; Hu Z; Haddad BR; Glasgow E; Riegel AT; Wellstein A
Oncogene; 2015 Nov; 34(48):5879-89. PubMed ID: 25772246
[TBL] [Abstract][Full Text] [Related]
8. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
9. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
10. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
11. αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.
Li P; Silvis MR; Honaker Y; Lien WH; Arron ST; Vasioukhin V
Genes Dev; 2016 Apr; 30(7):798-811. PubMed ID: 27013234
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
13. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
14. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
15. Dual Role of a C-Terminally Truncated Isoform of Large Tumor Suppressor Kinase 1 in the Regulation of Hippo Signaling and Tissue Growth.
Matsui Y; Zhang Y; Paulson RF; Lai ZC
DNA Cell Biol; 2019 Jan; 38(1):91-106. PubMed ID: 30461308
[TBL] [Abstract][Full Text] [Related]
16. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
18. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
19. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.
Ye XY; Luo QQ; Xu YH; Tang NW; Niu XM; Li ZM; Shen SP; Lu S; Chen ZW
J Cell Mol Med; 2015 Mar; 19(3):651-63. PubMed ID: 25712415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
